ResearchMoz added Latest Research Report titled ” Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 ” to it’s Large Report database.
This report provides an overview of the Genetic Disorders pipeline landscape, specifically focusing on muscular dystrophies. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Becker and Duchenne Muscular Dystrophy (BMD and DMD) and features dormant and discontinued projects. Both indications covered are inherited muscular dystrophies, a group of genetic, degenerative diseases primarily affecting voluntary muscles.
BMD, the first type of muscular dystrophy, leads to symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls. DMD is a condition which causes muscle weakness, and is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1070457
The size of these two pipelines ranges from just six in BMD to 108 in DMD. The majority of pipeline products for DMD target dystrophin which, as mentioned, is the causative gene for the disease. However, a number of products act on other molecular targets such as growth differentiation factor 8, nuclear factor kappa B and utrophin. The first two of these make up the pipeline for BMD, along with forkhead box protein 1B.
- Which companies are the most active within the pipeline for genetic disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of genetic disorder therapeutics?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 5
List of Figures 7
Genetic Disorder Cluster Muscular Dystrophy Report Coverage 8
Becker Muscular Dystrophy – Overview 8
Duchenne Muscular Dystrophy – Overview 8
Therapeutics Development 9
Becker Muscular Dystrophy 9
Duchenne Muscular Dystrophy 12
Therapeutics Assessment 22
Becker Muscular Dystrophy 22
Duchenne Muscular Dystrophy 30
Companies Involved in Therapeutics Development 38
Becker Muscular Dystrophy 38
Duchenne Muscular Dystrophy 40
Dormant Projects 63
Becker Muscular Dystrophy 63
Duchenne Muscular Dystrophy 64
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/